This biotechnology company is developing first-in-class therapeutics to promote neurogenesis for the potential treatment of central nervous system diseases.

Bolden Therapeutics is a biotechnology company developing first-in-class therapeutics to treat central nervous system diseases. The company's scientific co-founders, Dr. Justin Fallon and Dr. Ashley Webb have identified a key molecular pathway to stimulate neural stem cells to promote the birth of new neurons (neurogenesis) in the adult brain. The company is currently working on antisense oligonucleotides for this genetically validated target, with candidates ready for in vivo efficacy testing.